https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Oncol. 2009 Apr;34(4):951-622009-04-01 00:00:002021-11-15 17:02:15Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Pancreas 2009 Apr;38(3):e69-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Pancreas 2009 Apr;38(3):e69-742009-04-01 00:00:002019-02-15 08:52:34A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-192009-04-01 00:00:002019-02-15 08:46:47DCVax-Brain and DC vaccines in the treatment of GBM
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Apr;73(5):1538-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Apr;73(5):1538-442009-04-01 00:00:002019-02-15 09:17:35Use of the concept of equivalent biologically effective dose (BED) to quantify the contribution of hyperthermia to local tumor control in radiohyperthermia cervical cancer trials, and comparison with radiochemotherapy results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-402009-03-24 00:00:002019-02-15 08:49:29Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-16 / Oncologist 2009 Mar;14(3):240-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-16 / Oncologist 2009 Mar;14(3):240-522009-03-16 00:00:002019-02-15 08:32:27Immunotherapy of acute myeloid leukemia: current approaches
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Blood 2009 May;113(21):5167-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Blood 2009 May;113(21):5167-752009-03-11 00:00:002019-02-15 08:44:19Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Cancer Chemother. Pharmacol. 2009 Nov;64(6):1079-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Cancer Chemother. Pharmacol. 2009 Nov;64(6):1079-832009-03-11 00:00:002019-02-15 09:17:32Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-03 / Cancer Res. 2009 Mar;69(6):2685-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-03 / Cancer Res. 2009 Mar;69(6):2685-932009-03-03 00:00:002019-02-15 08:38:01Coordination of intratumoral immune reaction and human colorectal cancer recurrence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Future Oncol 2009 Mar;5(2):187-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Future Oncol 2009 Mar;5(2):187-962009-03-01 00:00:002019-02-15 09:23:58Promising novel immunotherapies and combinations for prostate cancer
